

## Editorial

## 2020 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards

Emmanuel J. Favaloro, PhD, FFS<sub>c</sub> (RCPA)<sup>1</sup>

<sup>1</sup>Sydney Centres for Thrombosis and Haemostasis, Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, Australia

Semin Thromb Hemost 2021;47:229–237.

Welcome to the latest of our Eberhard F. Mammen award announcements. As noted many times previously, Thieme, the publisher of *Seminars in Thrombosis and Hemostasis* (STH), has created the “Eberhard F. Mammen Excellence in Thrombosis and Hemostasis Awards” in honor of Eberhard Mammen (►Fig. 1), and in recognition of his contribution to this field and to the journal that he both founded and steered for over three decades (see ►Table 1 for relevant references). These awards began in 2009, under two categories; the current award details and conditions are as follows:

- Most popular article awards: Awarded to the authors of the most popular articles published in STH. The awards are determined by the Editor in Chief on the basis of user statistics from Thieme e-journals from the preceding 2 years. Prefaces, errata, letters to the editor, and editorials, and previous award-winning articles, are excluded from further consideration of these awards, which currently comprise two categories: one for “Open Access” articles, and another for a “General Category.” There are



**Fig. 1** Eberhard F. Mammen (1930–2008).

two major cash prizes of US\$1,000 for each category. In addition, winners of the “General Category” awards are granted “open access” status for these articles thereafter.

- Young investigator awards: Best presentation or meeting abstract by a young investigator—as presented or delivered to an international or large regional meeting on a topic related to the fields of thrombosis and hemostasis—and whose subject matter is determined to be in the spirit of Dr. Mammen. Up to six cash prizes of US\$1,000 are given in any year. There are some additional considerations and conditions for the award, and awardees are expected to prepare a review or other papers related to the topic of their presentation (or as otherwise agreed) for publication in STH. In general, previous award winners are excluded from a second award to enable more individuals to be recognized. After nominations are received, the awardees are selected by a vote of the senior editors of STH. Any potential conflicts of interest are managed by first identifying these, and then excluding those with potential conflicts from voting. Finally, given the current COVID-19 pandemic, many international congresses have become virtual meetings, and accordingly, virtual meeting presentations can also be considered for the award.

Further details of the awards and the award winners are posted online (<https://www.thieme-connect.com/products/ejournals/journal/10.1055/s-00000077>), and previous award winner announcements are also available in print (see ►Table 1 for a listing of relevant editorials published in this journal as related to the initiation of the Eberhard F. Mammen awards, as well as previous award announcements; these publications are also available for free download from the

**Address for correspondence**  
Emmanuel J. Favaloro, Sydney  
Centres for Thrombosis and  
Haemostasis, Department of  
Haematology, Institute of Clinical  
Pathology and Medical Research  
(ICPMR), Westmead Hospital,  
Westmead, NSW, 2145, Australia  
(e-mail: [emmanuel.favaloro@health.nsw.gov.au](mailto:emmanuel.favaloro@health.nsw.gov.au)).

**Issue Theme** Hemostatic and  
Nonhemostatic Effects of  
Heparan Sulfate Proteoglycans;  
Guest Editors: Yona Nadir, MD,  
PhD and Ton Lisman, PhD.

© 2021. Thieme. All rights reserved.  
Thieme Medical Publishers, Inc.,  
333 Seventh Avenue, 18th Floor,  
New York, NY 10001, USA

DOI <https://doi.org/10.1055/s-0041-1724120>.  
ISSN 0094-6176.

**Table 1** Listing of relevant editorials published in STH as related to the initiation of the Eberhard F. Mammen awards, as well as previous award announcements

1. Favalaro EJ. Welcome to a special issue of Seminars in Thrombosis and Hemostasis—the closing issue for 2008. <i>Semin Thromb Hemost</i> 2008;34:693–696
2. Favalaro EJ. A Tribute to Eberhard F. Mammen, M.D. (1930–2008). <i>Semin Thromb Hemost</i> 2008;34:703–708
3. Favalaro EJ. Welcome to the first issue of Seminars in Thrombosis and Hemostasis for 2009. <i>Semin Thromb Hemost</i> 2009;35:1–2.
4. Favalaro EJ. Winners of the inaugural Eberhard F. Mammen Award for most popular article. <i>Semin Thromb Hemost</i> 2009;35:587–590
5. Favalaro EJ. 2009 Eberhard F. Mammen Young Investigator Award winners. <i>Semin Thromb Hemost</i> 2010;36:469–470
6. Favalaro EJ. Winners of the 2010 Eberhard F. Mammen Award for most popular article during 2008–2009. <i>Semin Thromb Hemost</i> 2010;36(7):685–92.
7. Favalaro EJ. 2011 Eberhard F. Mammen Award announcements. <i>Semin Thromb Hemost</i> 2011;37(5):431–9.
8. Favalaro EJ. 2012 Eberhard F. Mammen Award announcements. <i>Semin Thromb Hemost</i> 2012;38:425–32.
9. Favalaro EJ. 2013 Eberhard F. Mammen Award announcements. <i>Semin Thromb Hemost</i> 2013;39:567–74.
10. Favalaro EJ. 2014 Eberhard F. Mammen award announcements: Part I—most popular articles. <i>Semin Thromb Hemost</i> 2014;40(4):407–12.
11. Favalaro EJ. 2014 Eberhard F. Mammen Award announcements: Part II - young investigator awards. <i>Semin Thromb Hemost</i> 2014;40(7):718–23.
12. Favalaro EJ. 2015 Eberhard F. Mammen Award announcements: Part I—most popular articles. <i>Semin Thromb Hemost</i> 2015;41(7):673–9.
13. Favalaro EJ. 2015 Eberhard F. Mammen Award announcements: Part II—young investigator awards. <i>Semin Thromb Hemost</i> 2015;41(8):809–15.
14. Favalaro EJ. 2016 Eberhard F. Mammen Award announcements: Part I - most popular articles. <i>Semin Thromb Hemost</i> 2016;42(4):325–30.
15. Favalaro EJ. 2016 Eberhard F. Mammen Award announcements: Part II—young investigator awards. <i>Semin Thromb Hemost</i> 2017;43(3):235–241.
16. Favalaro EJ. 2017 Eberhard F. Mammen Award announcements: Part I—most popular articles. <i>Semin Thromb Hemost</i> 2017;43(4):357–363.
17. Favalaro EJ. 2017 Eberhard F. Mammen Award announcements: Part II- young investigator awards. <i>Semin Thromb Hemost</i> 2018;44(2):81–88.
18. Favalaro EJ. 2018 Eberhard F. Mammen Award announcements: Part I—most popular articles. <i>Semin Thromb Hemost</i> 2018;44(3):185–192.
19. Favalaro EJ. 2018 Eberhard F. Mammen Award announcements: Part II—young investigator awards. <i>Semin Thromb Hemost</i> 2019;45(2):123–129.
20. Favalaro EJ. 2019 Eberhard F. Mammen Award announcements: Part I—most popular articles. <i>Semin Thromb Hemost</i> 2019;45(3):215–224.
21. Favalaro EJ. 2019 Eberhard F. Mammen Award announcements: Part II—young investigator awards. <i>Semin Thromb Hemost</i> 2020;46(2):105–113
22. Favalaro EJ. 2020 Eberhard F. Mammen Award announcements: Part I—most popular articles. <i>Semin Thromb Hemost</i> 2020;46(4):383–392.

journal Web site: <<https://www.thieme-connect.com/products/ejournals/journal/10.1055/s-00000077>>).

The winners of the 2020 Eberhard F. Mammen awards for the most popular articles from STH for the period of 2018 to 2019 inclusive were announced in an earlier issue of the journal.<sup>1</sup> It is therefore with great pleasure that we would like to announce the winners of the latest round of Young Investigator Awards.

As mentioned above, the Young Investigator Awards represent winners of the best presentation or meeting abstract by a young investigator—as presented or delivered to an international or large regional meeting (virtual meetings permissible)

on a topic related to the fields of thrombosis and hemostasis—and whose subject matter is determined to be in the spirit of Dr. Mammen. There are additional considerations given that the nominees' presentations are not always seen by all of the possible award nominators, being drawn from the editorial team of the journal. The latest winners are identified below and also in ► **Table 2**, with a running list of previous awardees, and the resulting publications in the journal, given in ► **Table 3**. The latest awardees were derived from a variety of meetings, including the latest meetings of the International Society on Thrombosis and Haemostasis (ISTH) and the American Society of Hematology. All meetings were held virtually.

**Table 2** Latest (2020) Eberhard F. Mammen Young Investigator Award winners

Awardee	Current affiliation(s)	Presentation(s) awarded	Proposed submission to STH
Hanny Al-Samkari	Division of Hematology/Oncology, Hereditary Hemorrhagic Telangiectasia Center, Massachusetts General Hospital, Harvard Medical School, United States	ISTH2020 ( <a href="https://www.isth2020.org/">https://www.isth2020.org/</a> ). Presentation: Thrombosis, bleeding, and the effect of anticoagulation on survival in critically ill patients with COVID-19 in the United States.	Systemic angiogenic inhibition to treat bleeding in hereditary hemorrhagic telangiectasia
Matthias M Engelen	Center for Molecular and Vascular Biology, Department of Cardiovascular Diseases, University Hospitals (UZ) Leuven, Leuven, Belgium	ISTH2020 ( <a href="https://www.isth2020.org/">https://www.isth2020.org/</a> ). Presentation: Incidence of venous thromboembolism in patients discharged after COVID-19 hospitalization.	Venous thromboembolism in patients discharged after COVID-19 hospitalization
Imre Varju, Hungary	Semmelweis University, Budapest, Hungary	ISTH2020 ( <a href="https://www.isth2020.org/">https://www.isth2020.org/</a> ). Presentation: Fibrinogen is citrullinated in venous thrombi and forms fragile clots with increased resistance to lysis	NETs at the crossroad of antithrombosis and thrombolysis
Ellen Driever	University Medical Center Groningen, the Netherlands	International Liver Congress (ILC 2020) ( <a href="https://ilc-congress.eu/programme-digital-ilc-2020/">https://ilc-congress.eu/programme-digital-ilc-2020/</a> ). Presentation: The VWF/ADAMTS13 imbalance, but not global coagulation or fibrinolysis, is associated with outcome and bleeding in patients with acute liver failure	Coagulation and inflammation in critically ill liver patients.
Christine Lee	Platelet and Thrombosis Research Laboratory, The ANZAC Research Institute, Concord Repatriation General Hospital, NSW Australia Faculty of Medicine and Health, University of Sydney, Sydney, NSW Australia	ASH2020 ( <a href="https://ash.confex.com/ash/2020/webprogram/start.html">https://ash.confex.com/ash/2020/webprogram/start.html</a> ). Presentation: Soluble platelet agonists expand the procoagulant surface in heparin-induced thrombocytopenia.	Procoagulant platelets in thrombotic conditions
Maria Selvadurai	Australian Centre for Blood Diseases, Monash University, Victoria, Australia	ASH2020 ( <a href="https://ash.confex.com/ash/2020/webprogram/start.html">https://ash.confex.com/ash/2020/webprogram/start.html</a> ). Presentation: Soluble platelet agonists expand the procoagulant surface in heparin-induced thrombocytopenia.	Mechanisms of thrombosis in HIT: an update

**Table 3** Eberhard F. Mammen Young Investigator Award winners from previous years

Awardee	Year awarded	Publication arising
Willem M. Lijfering	2009	Lijfering WM, Flinterman LE, Vandenbroucke JP, Rosendaal FR, Cannegieter SC. Relationship between venous and arterial thrombosis: a review of the literature from a causal perspective. <i>Semin Thromb Hemost</i> 2011 Nov;37(8):885–96.
Salley Pels	2009	Pels SG. Current therapies in primary immune thrombocytopenia. <i>Semin Thromb Hemost</i> 2011 Sep;37(6):621–30.
Adam Cuker	2010	Cuker A. Current and emerging therapeutics for heparin-induced thrombocytopenia. <i>Semin Thromb Hemost</i> 2012 Feb;38(1):31–7.
Giridhara Rao Jayandharan	2010	Jayandharan GR, Srivastava A, Srivastava A. Role of molecular genetics in hemophilia: from diagnosis to therapy. <i>Semin Thromb Hemost</i> 2012 Feb;38(1):64–78.
Timea Szanto	2010	Szántó T, Joutsu-Korhonen L, Deckmyn H, Lassila R. New insights into von Willebrand disease and platelet function. <i>Semin Thromb Hemost</i> 2012 Feb;38(1):55–63.

(Continued)

**Table 3** (Continued)

Awardee	Year awarded	Publication arising
Birgitta Salmela	2010	Salmela B, Joutsu-Korhonen L, Armstrong E, Lassila R. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. <i>Semin Thromb Hemost</i> 2012 Feb;38(1):23–30.
Pia Riittaa-Maria Siljander	2010	Aatonen M, Grönholm M, Siljander PR. Platelet-derived microvesicles: multitasking participants in intercellular communication. <i>Semin Thromb Hemost</i> 2012 Feb;38(1):102–13.
Romarc Lacroix	2011	Lacroix R, Dignat-George F. Microparticles: new protagonists in pericellular and intravascular proteolysis. <i>Semin Thromb Hemost</i> 2013 Feb;39(1):33–9.
Brad McEwen	2011	McEwen BJ, Morel-Kopp MC, Chen W, Tofler GH, Ward CM. Effects of omega-3 polyunsaturated fatty acids on platelet function in healthy subjects and subjects with cardiovascular disease. <i>Semin Thromb Hemost</i> 2013 Feb;39(1):25–32.
Neil A. Goldenberg	2011	Bernard TJ, Armstrong-Wells J, Goldenberg NA. The institution-based prospective inception cohort study: design, implementation, and quality assurance in pediatric thrombosis and stroke research. <i>Semin Thromb Hemost</i> 2013 Feb;39(1):10–4.
Vivien Chen	2011	Chen VM. Tissue factor de-encryption, thrombus formation, and thiol-disulfide exchange. <i>Semin Thromb Hemost</i> 2013 Feb;39(1):40–7.
Joseph E. Italiano, Jr.	2011	Italiano JE Jr. Unraveling mechanisms that control platelet production. <i>Semin Thromb Hemost</i> 2013 Feb;39(1):15–24.
Vivian Xiaoyan Du	2012/2013	Du VX, Huskens D, Maas C, Al Dieri R, de Groot PG, de Laat B. New insights into the role of erythrocytes in thrombus formation. <i>Semin Thromb Hemost</i> 2014 Feb;40(1):72–80.
Andrew Yee	2012/2013	Yee A, Kretz CA. Von Willebrand factor: form for function. <i>Semin Thromb Hemost</i> 2014 Feb;40(1):17–27.
Sarah O'Brien	2012/2013	O'Brien SH. Contraception-related venous thromboembolism in adolescents. <i>Semin Thromb Hemost</i> 2014 Feb;40(1):66–71.
Veronica Flood	2012/2013	Flood VH. Perils, problems, and progress in laboratory diagnosis of von Willebrand disease. <i>Semin Thromb Hemost</i> 2014 Feb;40(1):41–8.
Julie Tange	2012/2013	Tange JI, Grill D, Koch CD, Ybabez RJ, Krekelberg BJ, Fylling KA, Wiese CR, Baumann NA, Block DR, Karon BS, Chen D, Pruthi RK. Local verification and assignment of mean normal prothrombin time and international sensitivity index values across various instruments: recent experience and outcome from North America. <i>Semin Thromb Hemost</i> 2014 Feb;40(1):115–20.
Kent Chapman	2012/2013	Chapman K, Yuen S. Therapy for thrombotic thrombocytopenia purpura: past, present, and future. <i>Semin Thromb Hemost</i> 2014 Feb;40(1):34–40.
Andreas Tiede	2014	Tiede A, Werwitzke S, Scharf RE. Laboratory diagnosis of acquired hemophilia a: limitations, consequences, and challenges. <i>Semin Thromb Hemost</i> 2014 Oct;40(7):803–11.
Wendy Lim	2014	Lim W. Thrombotic risk in the antiphospholipid syndrome. <i>Semin Thromb Hemost</i> 2014 Oct;40(7):741–6.
Susana Nobre Fernandes	2014	Fernandes S, Carvalho M, Lopes M, Araújo F. Impact of an individualized prophylaxis approach on young adults with severe hemophilia. <i>Semin Thromb Hemost</i> 2014 Oct;40(7):785–9.
Maria Elisa Mancuso	2014	Mancuso ME, Fasulo MR. Thrombin generation assay as a laboratory monitoring tool during by-passing therapy in patients with hemophilia and inhibitors. <i>Semin Thromb Hemost</i> 2016 Feb;42(1):30–5.
Coen Maas	2014	Tersteeg C, Fijnheer R, Deforche L, Pasterkamp G, de Groot PG, Vanhoor-elbeke K, de Maat S, Maas C. Keeping von Willebrand factor under control: alternatives for ADAMTS13. <i>Semin Thromb Hemost</i> 2016 Feb;42(1):9–17.
Riten Kumar	2014	Kumar R, Dunn A, Carcao M. Changing Paradigm of hemophilia management: extended half-life factor concentrates and gene therapy. <i>Semin Thromb Hemost</i> 2016 Feb;42(1):18–29.

Table 3 (Continued)

Awardee	Year awarded	Publication arising
Juraj Sokol	2015	Sokol J, Skerenova M, Jedinakova Z, Simurda T, Skornova I, Stasko J, Kubisz P. Progress in the understanding of sticky platelet syndrome. <i>Semin Thromb Hemost</i> 2017;43(1):8–13
Ljubica Jovanović	2015	Jovanovic L, Antonijevic N, Novakovic T, Savic N, Terzic B, Zivkovic I, Radovanovic N, Asanin M. Practical aspects of monitoring of antiplatelet therapy. <i>Semin Thromb Hemost</i> 2017;43(1):14–23
Lucia Stanciakova	2015	Stanciakova L, Dobrotova M, Jedinakova Z, Duraj L, Skornova I, Korinkova L, Holly P, Danko J, Stasko J, Kubisz P. Monitoring of hemostasis and management of anticoagulant thromboprophylaxis in pregnant women with increased risk of fetal loss. <i>Semin Thromb Hemost</i> 2016 Sep;42(6):612–21.
Tina Biss	2015	Biss TT. Venous thromboembolism in children: is it preventable? <i>Semin Thromb Hemost</i> 2016 Sep;42(6):603–11.
Tobias Fuchs	2015	Jiménez-Alcázar M, Kim N, Fuchs TA. Circulating extracellular DNA: cause or consequence of thrombosis? <i>Semin Thromb Hemost</i> 2017 Sep;43(6):553–561
Jonathan M. Coutinho	2015	Silvis SM, Middeldorp S, Zuurbier SM, Cannegieter SC, Coutinho JM. Risk factors for cerebral venous thrombosis. <i>Semin Thromb Hemost</i> 2016 Sep;42(6):622–31.
Soundarya Selvam	2016	Selvam S, James P. Angiodysplasia in von Willebrand disease: understanding the clinical and basic science. <i>Semin Thromb Hemost</i> 2017 Sep;43(6):572–580.
Vincent Muczynski	2016	Muczynski V, Christophe OD, Denis CV, Lenting PJ. Emerging therapeutic strategies in the treatment of hemophilia A. <i>Semin Thromb Hemost</i> 2017 Sep;43(6):581–590.
Karen Schreiber	2016	Schreiber K, Breen K, Cohen H, Jacobsen S, Middeldorp S, Pavord S, Regan L, Roccatello D, Robinson SE, Sciascia S, Seed PT, Watkins L, Hunt BJ. Hydroxychloroquine to Improve Pregnancy Outcome in Women with Antiphospholipid Antibodies (HYPATIA) Protocol: a multinational randomized controlled trial of hydroxychloroquine versus placebo in addition to standard treatment in pregnant women with antiphospholipid syndrome or antibodies. <i>Semin Thromb Hemost</i> 2017 Sep;43(6):562–571.
Jasmine Wee Ting Tay	2016	Tay J, Tiao J, Hughes Q, Jorritsma J, Gilmore G, Baker R. Circulating microRNA as thrombosis sentinels: caveats and considerations. <i>Semin Thromb Hemost</i> 2018 Apr;44(3):206–215.
Adi J. Klil-Drori	2016	Klil-Drori AJ, Tagalakis V. Direct oral anticoagulants in end-stage renal disease. <i>Semin Thromb Hemost</i> 2018 Jun;44(4):353–363.
Lindsey A. George	2016	Submission pending.
Ivar van Asten	2017	van Asten I, Schutgens REG, Urbanus RT. Toward Flow Cytometry based platelet function diagnostics. <i>Semin Thromb Hemost</i> 2018 Apr;44(3):197–205.
Elodie Laridan	2017	Laridan E, Martinod K, De Meyer SF. Neutrophil extracellular traps in arterial and venous thrombosis. <i>Semin Thromb Hemost</i> 2019 Feb;45(1):86–93.
Leonardo Pasalic	2017	Blennerhassett R, Curnow J, Pasalic L. Immune-mediated thrombotic thrombocytopenic purpura: a narrative review of diagnosis and treatment in adults. <i>Semin Thromb Hemost</i> 2020 Apr;46(3):289–301
Yvonne Brennan	2017	Brennan Y, Favaloro EJ, Curnow J. To maintain or cease non-vitamin K antagonist oral anticoagulants prior to minimal bleeding risk procedures: a review of evidence and recommendations. <i>Semin Thromb Hemost</i> 2019 Mar;45(2):171–179.
Georgia McCaughan	2017	Submission pending.
Mark Schreuder, MSc	2018	Schreuder M, Reitsma PH, Bos MHA. Reversal Agents for the Direct Factor Xa inhibitors: biochemical mechanisms of current and newly emerging therapies. <i>Semin Thromb Hemost</i> 2020 Nov;46(8):986–998

(Continued)

**Table 3** (Continued)

Awardee	Year awarded	Publication arising
James McFadyen MBBS FRACP PhD	2018	Stevens H, McFadyen JD. Platelets as central actors in thrombosis-reprising an old role and defining a new character. <i>Semin Thromb Hemost</i> 2019 Nov;45(8):802–809.
David Rabbolini BSc MBCh (Witw.), FRACP FRCPA PhD	2018	Mason AG, Rabbolini DJ. The current role of platelet function testing in clinical practice. <i>Semin Thromb Hemost</i> , in press.
Janka Zolkova, MSc	2018	Zolkova J, Sokol J, Simurda T, Vadelova L, Snahnicanova Z, Loderer D, Dobrotova M, Ivankova J, Skornova I, Lasabova Z, Kubisz P, Stasko J. Genetic background of von Willebrand disease: history, current state and future perspectives. <i>Semin Thromb Hemost</i> 2020 Jun;46(4):484–500
Tomáš Bolek MD	2018	Bolek T, Samoš M, Škorňová I, Galajda P, Staško J, Kubisz P, Mokáň M. Proton pump inhibitors and dabigatran therapy: impact on gastric bleeding and dabigatran plasma levels. <i>Semin Thromb Hemost</i> 2019 Nov;45(8):846–850.
Fraser McCrae BSc (Hons)	2018	Submission pending.
Elisa Danese	2019	Danese E, Montagnana M, Gelati M, Lippi G. The role of epigenetics in the regulation of hemostatic balance. <i>Semin Thromb Hemost</i> 2021 Feb;47(1):53–62.
Soracha Ward	2019	Ward S, O'Sullivan JM, O'Donnell JS. The biological significance of von Willebrand factor O linked glycosylation. <i>Semin Thromb Hemost</i> 2021, in press.
Jonathan Douxfils	2019	Douxfils J, Morimont L, Bouvy C. Oral contraceptives and venous thromboembolism: focus on testing that may enable prediction and assessment of the risk. <i>Semin Thromb Hemost</i> 2020 Nov;46(8):872–886.
Erik Klok	2019	Boon GJAM, Huisman MV, Klok FA. Why, whom, and how to screen for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. <i>Semin Thromb Hemost</i> 2020 Dec 21. (e-pub ahead of print). doi:10.1055/s-0040-1718925. PMID: 33348411.
Michelle Lavin	2019	Byrne B, Ryan K, Lavin M. Current challenges in the peripartum management of women with von Willebrand Disease. <i>Semin Thromb Hemost</i> 2021, in press.
Deeksha Khialani	2019	Khialani D, Rosendaal F, Vlieg AVH. Hormonal contraceptives and the risk of venous thrombosis. <i>Semin Thromb Hemost</i> 2020 Nov;46(8):865–871.

As often occurs with these awards, the current crop of winners reflects a variety of “Young Investigators” at various stages of their careers. Some awardees are just starting out on their journey in science or medicine, while others are better established in their careers and crossing over into the next phase of their life where they will soon no longer be called “young” investigators.

Hanny Al-Samkari (► **Fig. 2**) is an Instructor in Medicine at Harvard Medical School and a clinical investigator in the Massachusetts General Hospital (MGH) Division of Hematology, where he focuses on bleeding disorders and rare hematologic diseases. He also serves as the Associate Director of the MGH Hereditary Hemorrhagic Telangiectasia (HHT) Center of Excellence. His clinical and research focuses include several areas within hemostasis, including systemic therapies for bleeding in HHT, thrombopoietic growth factors in various thrombocytopenias, and various topics in diagnosis and treatment of immune thrombocytopenia. He currently serves as principle investigator for several clinical trials in these areas. From the start of the COVID-19 pandemic, he has also been very active in investigation of bleeding, thrombosis, and anticoagu-

lation in patients with COVID-19. He has published over 70 articles in peer-reviewed journals, serves on several national and international committees including the working group for the Second International HHT Guidelines, and is the Hematology Associate Editor for the Orphanet Journal of Rare Diseases.

Matthias Engelen (► **Fig. 3**) is a PhD candidate at the University of Leuven. After he graduated as a medical doctor in 2017, he trained in internal medicine as a junior doctor at the University Hospitals Leuven. His master's dissertation investigated the clinical use of thrombolytic therapy. Last year, he started working on contact activation in cardiovascular diseases as a PhD researcher at the University of Leuven, under the supervision of Prof. Dr. Thomas Vanassche, Prof. Dr. Christophe Vandembrielle, and Prof. Dr. Peter Verhamme. His project was awarded with best project by the Belgian Society of Thrombosis and Hemostasis in 2019, and has so far resulted in several abstracts and a late-breaking presentation at international congresses.

Imre Varju (► **Fig. 4**) is a Fulbright Scholar in medical science and a Health Communication Specialist with over 10 years of experience in the field of hemostasis, with a

special focus on the impact of neutrophil extracellular traps on thrombus formation and dissolution. He obtained his MD and PhD at Semmelweis University, Hungary, completed postdoctoral trainings at the Hungarian Academy of Sciences, the National Institute for Biological Standards for Control, United Kingdom, and at Harvard Medical School, and obtained his MPH at Columbia University. He is a Senior Lecturer at Semmelweis University and holds a Manager, Learning Strategy position at FCB Health New York.

Ellen Driever (→ Fig. 5) is a PhD candidate from the University Medical Center Groningen, the Netherlands. Her research is about thrombosis and hemostasis in patients with liver diseases, with a focus on the pathogenesis and treatment of portal vein thrombosis in cirrhotic patients. She studied Pharmacy in Groningen (the Netherlands), and also completed a research project at the Department of Biological Engineering at the Massachusetts Institute of Technology (Boston, MA).

Christine Lee (→ Fig. 6) is a first-year postdoctoral researcher under the supervision of Associate Professor Vivien Chen at the ANZAC Research Institute and University of Sydney. She is passionate in undertaking studies with clear translational potential and developing assays that will impact on the clinical outcomes of patients. In 2019, she completed her PhD under the supervision of Professor Elizabeth Gardiner and Dr. Philip Choi at the John Curtin School of Medical Research, the Australian National University. Her PhD thesis investigated the shedding mechanism of the major platelet collagen receptor, glycoprotein VI, in healthy donors and in patients with heparin-induced thrombocytopenia.

Maria Selvadurai (→ Fig. 7) is a recent MD-PhD graduate from Monash University and a junior doctor at Alfred Health. She undertook her final year MD research project on soluble platelet agonists in heparin-induced thrombocytopenia at the ANZAC Research Institute, Sydney, under the supervision of Dr. Vivien Chen and Dr. Christine Lee. Her PhD, completed in 2019, examined the cellular effects of class II PI3Ks in platelets, and the biological implications of targeting these pharmacologically as a novel antithrombotic strategy, and was supervised by A/Prof. Justin Hamilton and Prof. Harshal Nandurkar at the Australian Centre for Blood Diseases, Monash University.

All award winners were elated to hear that they had been selected to receive an Eberhard F. Mammen Young Investigator award, and provided the following additional commentary.

“I am deeply honored and privileged to have been nominated and selected for an Eberhard F. Mammen Young Investigator Award. Dr. Mammen was a luminary in our field, and it is particularly meaningful for me as a hemostasis investigator to receive an award in his honor. I would like to thank my many research collaborators and mentors, without whom my work would not have been possible. I would also like to thank Dr. Falavero and the editorial team of *Seminars in Thrombosis and Hemostasis* for their recognition of our work. The future of hemostasis research has never been more promising, and together with my colleagues I am certain we will advance the care




Fig. 2 Young Investigator Award winner Hanny Al-Samkari.

of patients with hereditary hemorrhagic telangiectasia, thrombocytopenias, and many other bleeding and thrombotic disorders.”

- Hanny Al-Samkari (→ Fig. 2)

“I am very grateful and honored to be awarded an Eberhard F. Mammen Young Investigator Award for our research on venous thromboembolism in patients discharged after COVID-19 hospitalization, as presented at the ISTH meeting in July 2020 (abstract number LB/CO01.3). I would like to thank the Editor in Chief, Dr. Falavero, and the editorial board of *Seminars in Thrombosis and Hemostasis* for this wonderful recognition. As this research was very much a team effort, I would like to thank my supervisors Prof. Vanassche, Vandenbrielle, and Verhamme for their excellent mentorship in these challenging times and the Department of Cardiovascular Diseases—particularly the Vascular Center—for making this research possible.”

- Matthias Engelen (→ Fig. 3)

“I am beyond honored to have received an Eberhard F. Mammen Young Investigator Award. To me, this recognition has special value in an era that demonstrates how clear communication of science is just as important as science itself. To my science family: Dr. Krasimir Kolev's lab at Semmelweis, Dr. Colin Longstaff's lab at NIBSC, and



Fig. 3 Young Investigator Award winner Matthias Engelen.



**Fig. 4** Young Investigator Award winner Imre Varju.

Dr. Denisa Wagner's lab at Harvard—thank you for your mentorship and collaboration. To my Public Health and Health Communication families at Columbia University, FCB Health and beyond: thank you for your continuous support. Finally, to the selection committee: thank you for your consideration and this humbling recognition.”

- Imre Varju (► **Fig. 4**)

“I am honored to be awarded an Eberhard F. Mammen Young Investigator Award. I very much appreciate the recognition for my work on the association between bleeding or outcome and the hemostatic state in patients with acute liver failure. This award acknowledges a team effort, and this achievement would not have been possible without the support of the entire team, in particular my supervisor Professor Ton Lisman. This award will thrive my future research efforts.”

- Ellen Driever (► **Fig. 5**)

“I am humbled and honored to receive an Eberhard F. Mammen Young Investigator Award for our work on procoagulant platelets in heparin-induced thrombocytopenia. This award is a testament to the invaluable support and mentorship I received from my supervisors and mentors, Associate Professor Vivien Chen, and Professor Elizabeth Gardiner, and is a recognition of the team effort by my coauthors and colleagues. As a first-year postdoc-



**Fig. 5** Young Investigator Award winner Ellen Driever.



**Fig. 6** Young Investigator Award winner Christine Lee.

toral researcher, this award spurs me on to continue my contribution in this field.”

- Christine Lee (► **Fig. 6**)

“It is an honor to be awarded a 2020 Eberhard F. Mammen Young Investigator Award together with my colleague Dr. Christine Lee. I have been inspired by a number of previous winners of this award, and it is a huge privilege to follow in their footsteps. I would like to thank the editorial team of *Seminars in Thrombosis and Haemostasis* for selecting our presentation for this award, and Dr. Emmanuel Favaloro for delivering the good news. I am also extremely grateful to Dr. Vivien Chen and Dr. Lee for the fantastic opportunity to work on this project with them, and for their wonderful support and mentorship. Finally, I would like to thank the past and present members of the Platelet and Thrombosis Laboratory at the ANZAC Research Institute, without whose important contributions over many years this project would not have been possible.”

- Maria Selvadurai (► **Fig. 7**)

In keeping with previous editorials, I have again reviewed the Young Investigator awardees from previous years as well as the outcome of their subsequent submissions to *STH*, as summarized in ► **Table 3**. The most recent contributions are also listed in the reference list.<sup>2–15</sup> I previously mentioned my personal gratification that most of the papers from earlier



**Fig. 7** Young Investigator Award winner Maria Selvadurai.



years have subsequently appeared in several annual top 100 listings. Of further interest, some of these papers or the young investigators themselves have subsequently won one of the most popular awards. It is also motivating to observe that several of the Young Investigator awardees were coauthors on other contributions to STH that were also listed in these most popular listings.

I look forward to seeing the careers of the current and past Young Investigator Award winners to continue to develop. The above also infers that very high bars are now established for future Young Investigator awardees, and I wish all awardees the best of luck to exceed the precedence set by earlier award winners.

#### Conflict of Interest

None declared.

#### References

- 1 Favalaro EJ. 2020 Eberhard F. Mammen Award announcements: part I—most popular articles. *Semin Thromb Hemost* 2020;46(04):383–392
- 2 Tay J, Tiao J, Hughes Q, Jorritsma J, Gilmore G, Baker R. Circulating microRNA as thrombosis sentinels: caveats and considerations. *Semin Thromb Hemost* 2018;44(03):206–215
- 3 Klil-Drori AJ, Tagalakis V. Direct oral anticoagulants in end-stage renal disease. *Semin Thromb Hemost* 2018;44(04):353–363
- 4 van Asten I, Schutgens REG, Urbanus RT. Toward flow cytometry based platelet function diagnostics. *Semin Thromb Hemost* 2018;44(03):197–205
- 5 Laridan E, Martinod K, De Meyer SF. Neutrophil extracellular traps in arterial and venous thrombosis. *Semin Thromb Hemost* 2019;45(01):86–93
- 6 Blennerhassett R, Curnow J, Pasalic L. Immune-mediated thrombotic thrombocytopenic purpura: a narrative review of diagnosis and treatment in adults. *Semin Thromb Hemost* 2020;46(03):289–301
- 7 Brennan Y, Favalaro EJ, Curnow J. To maintain or cease non-vitamin K antagonist oral anticoagulants prior to minimal bleeding risk procedures: a review of evidence and recommendations. *Semin Thromb Hemost* 2019;45(02):171–179
- 8 Schreuder M, Reitsma PH, Bos MHA. Reversal agents for the direct factor Xa inhibitors: biochemical mechanisms of current and newly emerging therapies. *Semin Thromb Hemost* 2020;46(08):986–998
- 9 Stevens H, McFadyen JD. Platelets as central actors in thrombosis—reprising an old role and defining a new character. *Semin Thromb Hemost* 2019;45(08):802–809
- 10 Zolkova J, Sokol J, Simurda T, et al. Genetic background of von Willebrand disease: history, current state, and future perspectives. *Semin Thromb Hemost* 2020;46(04):484–500
- 11 Bolek T, Samoř M, Škorňová I, et al. Proton pump inhibitors and dabigatran therapy: impact on gastric bleeding and dabigatran plasma levels. *Semin Thromb Hemost* 2019;45(08):846–850
- 12 Danese E, Montagnana M, Gelati M, Lippi G. The role of epigenetics in the regulation of hemostatic balance. *Semin Thromb Hemost* 2020;47(01):53–62
- 13 Douxfils J, Morimont L, Bouvy C. Oral contraceptives and venous thromboembolism: focus on testing that may enable prediction and assessment of the risk. *Semin Thromb Hemost* 2020;46(08):872–886
- 14 Boon GJAM, Huisman MV, Klok FA. Why, whom, and how to screen for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. *Semin Thromb Hemost* 2020 (e-pub ahead of print). . Doi: 10.1055/s-0040-1718925
- 15 Khialani D, Rosendaal F, Vlieg AVH. Hormonal contraceptives and the risk of venous thrombosis. *Semin Thromb Hemost* 2020;46(08):865–871